SG11202012576QA - Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer - Google Patents
Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancerInfo
- Publication number
- SG11202012576QA SG11202012576QA SG11202012576QA SG11202012576QA SG11202012576QA SG 11202012576Q A SG11202012576Q A SG 11202012576QA SG 11202012576Q A SG11202012576Q A SG 11202012576QA SG 11202012576Q A SG11202012576Q A SG 11202012576QA SG 11202012576Q A SG11202012576Q A SG 11202012576QA
- Authority
- SG
- Singapore
- Prior art keywords
- platinum
- combination
- treating cancer
- antineoplastic agents
- based antineoplastic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382432 | 2018-06-18 | ||
| PCT/IB2019/000812 WO2019243900A2 (en) | 2018-06-18 | 2019-06-17 | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012576QA true SG11202012576QA (en) | 2021-01-28 |
Family
ID=62837845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012576QA SG11202012576QA (en) | 2018-06-18 | 2019-06-17 | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210187106A1 (en) |
| EP (1) | EP3806899A2 (en) |
| JP (2) | JP7379390B2 (en) |
| KR (1) | KR20210022065A (en) |
| CN (1) | CN112955178A (en) |
| AU (1) | AU2019291307B2 (en) |
| CA (1) | CA3103369A1 (en) |
| EA (1) | EA202092964A1 (en) |
| IL (1) | IL279444A (en) |
| MA (1) | MA52300A (en) |
| SG (1) | SG11202012576QA (en) |
| WO (1) | WO2019243900A2 (en) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | Modifications of or for denatured antibodies |
| LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
| AU4231393A (en) * | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| EP1141024B1 (en) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2363358B1 (en) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | THERAPEUTIC AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AN INDESEABLE CELLULAR PROLIFERATION. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| JP2017527582A (en) | 2014-09-10 | 2017-09-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Signaling pathway mediated by K-Ras and method of targeting malignant diseases with anti-hLIF antibody |
| CA2983126A1 (en) | 2015-04-17 | 2016-10-20 | Morphotek, Inc. | Methods for treating lung cancer |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| EP3794031A2 (en) * | 2018-05-14 | 2021-03-24 | MedImmune Limited | Antibodies against lif and dosage forms thereof |
-
2019
- 2019-06-17 AU AU2019291307A patent/AU2019291307B2/en active Active
- 2019-06-17 CA CA3103369A patent/CA3103369A1/en active Pending
- 2019-06-17 JP JP2020570163A patent/JP7379390B2/en active Active
- 2019-06-17 WO PCT/IB2019/000812 patent/WO2019243900A2/en unknown
- 2019-06-17 CN CN201980053679.1A patent/CN112955178A/en active Pending
- 2019-06-17 SG SG11202012576QA patent/SG11202012576QA/en unknown
- 2019-06-17 MA MA052300A patent/MA52300A/en unknown
- 2019-06-17 EA EA202092964A patent/EA202092964A1/en unknown
- 2019-06-17 KR KR1020217001441A patent/KR20210022065A/en unknown
- 2019-06-17 US US17/252,449 patent/US20210187106A1/en active Pending
- 2019-06-17 EP EP19782687.8A patent/EP3806899A2/en active Pending
-
2020
- 2020-12-14 IL IL279444A patent/IL279444A/en unknown
-
2023
- 2023-11-01 JP JP2023187689A patent/JP2024023212A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019291307A1 (en) | 2021-02-04 |
| JP2024023212A (en) | 2024-02-21 |
| EA202092964A1 (en) | 2021-03-30 |
| AU2019291307B2 (en) | 2024-04-04 |
| WO2019243900A3 (en) | 2020-03-05 |
| WO2019243900A2 (en) | 2019-12-26 |
| KR20210022065A (en) | 2021-03-02 |
| US20210187106A1 (en) | 2021-06-24 |
| JP7379390B2 (en) | 2023-11-14 |
| EP3806899A2 (en) | 2021-04-21 |
| CN112955178A (en) | 2021-06-11 |
| MA52300A (en) | 2021-04-21 |
| CA3103369A1 (en) | 2019-12-26 |
| IL279444A (en) | 2021-01-31 |
| JP2021533084A (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272948A (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| IL255189B2 (en) | A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer | |
| IL284199A (en) | Csf1r inhibitors for use in treating cancer | |
| IL282663A (en) | Bt1718 for use in treating cancer | |
| IL269710A (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers | |
| IL281999A (en) | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer | |
| IL281495A (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
| IL277918A (en) | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer | |
| HUE053236T2 (en) | Combining adenovirus and checkpoint inhibitors for treating cancer | |
| WO2017019721A3 (en) | Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer | |
| ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
| HK1258235A1 (en) | Inhibitors of pi3k p-delta 110 for use in delivery of viruses in the treatment of cancer | |
| IL279444A (en) | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer | |
| GB201709417D0 (en) | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer | |
| IL283687A (en) | Usp19 inhibitors for use in therapy | |
| IL277038A (en) | Bexarotene derivatives and their use in treating cancer | |
| PT3601296T (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers | |
| HUP1900281A1 (en) | Use of monoamine-oxidase-b inhibitors in the prevention or treatment of prostate cancer | |
| EP3829564C0 (en) | Curcumin and homotaurine for use in preventing or treating cognitive decline forms | |
| PT3813832T (en) | Compounds for use in preventing or treating cancer |